Tech Company Financing Transactions
AMLo Biosciences Funding Round
AMLo Biosciences closed a $3.2 million venture capital round on 4/21/2022. Investors included Ascension Ventures, Conduit EIS Impact Fund and Esperante BV.
Transaction Overview
Company Name
Announced On
4/21/2022
Transaction Type
Venture Equity
Amount
$3,200,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Gosforth Park Avenue Newcastle upon Tyne
Longbenton, NE12 8EG
UK
Longbenton, NE12 8EG
UK
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Developer of a diagnostic kit for melanoma intended to identify patients' true risk of disease progression. The company's kit provides prognostic tests for early AJCC Stage I and Stage II melanoma identification, stratifying patients to the most appropriate treatments and follow-up, enabling patients in reducing the psychological burden as well as saving health authorities millions of pounds in unnecessary patient surveillance.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Marie Labus
Chief Scientific Officer
Penny Lovat
Browse more venture capital transactions:
Prev: 4/21/2022: Labster venture capital transaction
Next: 4/21/2022: Jarvis ML venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs